CN114450004A - 用于治疗狗的慢性肾脏病的替米沙坦 - Google Patents

用于治疗狗的慢性肾脏病的替米沙坦 Download PDF

Info

Publication number
CN114450004A
CN114450004A CN202080049786.XA CN202080049786A CN114450004A CN 114450004 A CN114450004 A CN 114450004A CN 202080049786 A CN202080049786 A CN 202080049786A CN 114450004 A CN114450004 A CN 114450004A
Authority
CN
China
Prior art keywords
telmisartan
upc
period
treatment
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080049786.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·M·特拉斯
A·埃里克森科尔曼
B·N·费雷拉德莫拉洛伦索
K·E·克里维
S·A·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Georgia
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
University Georgia
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Georgia, Boehringer Ingelheim Vetmedica GmbH filed Critical University Georgia
Publication of CN114450004A publication Critical patent/CN114450004A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080049786.XA 2019-07-09 2020-04-30 用于治疗狗的慢性肾脏病的替米沙坦 Pending CN114450004A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
US62/871,752 2019-07-09
PCT/US2020/030579 WO2021006941A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Publications (1)

Publication Number Publication Date
CN114450004A true CN114450004A (zh) 2022-05-06

Family

ID=70775531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049786.XA Pending CN114450004A (zh) 2019-07-09 2020-04-30 用于治疗狗的慢性肾脏病的替米沙坦

Country Status (10)

Country Link
US (1) US20220218671A1 (https=)
EP (1) EP3996705A1 (https=)
JP (2) JP2022540074A (https=)
KR (1) KR20220054291A (https=)
CN (1) CN114450004A (https=)
BR (1) BR112022000315A2 (https=)
CA (1) CA3142876A1 (https=)
MX (1) MX2022000429A (https=)
TW (1) TW202116305A (https=)
WO (1) WO2021006941A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220054292A (ko) 2019-07-09 2022-05-02 베링거잉겔하임베트메디카게엠베하 개의 고혈압 치료를 위한 텔미사르탄

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3648761T (pt) 2017-07-07 2024-06-05 Boehringer Ingelheim Vetmedica Gmbh Telmisartan para a profilaxia ou tratamento de hipertensão em gatos

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.C.BUGBEE ET AL: ""Telmisartan Treatment of RefractoryProteinuria in a Dog"", 《JOURNAL OF VETERINARY INTERNAL MEDICINE》, vol. 28, no. 6, pages 1871 - 1874, XP055718581, DOI: 10.1111/jvim.12471 *

Also Published As

Publication number Publication date
US20220218671A1 (en) 2022-07-14
EP3996705A1 (en) 2022-05-18
KR20220054291A (ko) 2022-05-02
JP2022540074A (ja) 2022-09-14
CA3142876A1 (en) 2021-01-14
BR112022000315A2 (pt) 2022-02-22
AU2020311280A1 (en) 2022-02-24
TW202116305A (zh) 2021-05-01
JP2025120167A (ja) 2025-08-15
WO2021006941A1 (en) 2021-01-14
MX2022000429A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
CA2665435C (en) Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
US20080206237A1 (en) Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent
JP2025120167A (ja) イヌの慢性腎臓病の治療のためのテルミサルタン
ES2979279T3 (es) Telmisartán para la profilaxis o el tratamiento de la hipertensión en gatos
JP2025115405A (ja) イヌの高血圧の治療のためのテルミサルタン
KR102505720B1 (ko) 특발성 폐섬유화증의 치료를 위한 h4 작용제 분자의 용도
RU2832966C2 (ru) Телмисартан для лечения хронической болезни почек у собак
AU2020311280B2 (en) Telmisartan for the treatment of chronic kidney disease in dogs
RU2830555C2 (ru) Телмисартан для лечения гипертонии у собак
AU2020310059B2 (en) Telmisartan for the treatment of hypertension in dogs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination